Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Capital Medical University | OTHER |
| Peking Union Medical College | OTHER |
| Guangdong Provincial People's Hospital | OTHER |
| Nanjing Medical University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. The relative merits of each strategy have not been extensively studied. Our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic AF.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Antiarrythmic Drugs | Active Comparator |
| |
| ablation | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| catheter ablation | Procedure | circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants with all-cause death | 3 month | |
| Number of participants with all-cause death | 12 month | |
| Number of participants with all-cause death | 24 month | |
| Number of participants with all-cause death | 36 month | |
| severe blooding complications | 3 month | |
| severe blooding complications | 12 month | |
| severe blooding complications | 24 month | |
| severe blooding complications | 36 month | |
| cardio-cerebrovascular complications | 3 month | |
| cardio-cerebrovascular complications | 12 month | |
| cardio-cerebrovascular complications | 24 month | |
| cardio-cerebrovascular complications |
| Measure | Description | Time Frame |
|---|---|---|
| recurrence of atrial arrhythmias (AF, AFL, AT) | 3 month | |
| recurrence of atrial arrhythmias (AF, AFL, AT) | 12 month | |
| recurrence of atrial arrhythmias (AF, AFL, AT) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Cong xin Huang, doctor | Contact | 13907131546 | huangcongxin@yahoo.com.cn |
| Name | Affiliation | Role |
|---|---|---|
| Cong xin Huang, doctor | Renmin Hospital of Wuhan University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Renmin Hospital of Wuhan University | Recruiting | Wuhan | Hubei | China |
Not provided
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| ID | Term |
|---|---|
| D001145 | Arrhythmias, Cardiac |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| D017115 | Catheter Ablation |
| D002121 | Calcium Channel Blockers |
| ID | Term |
|---|---|
| D000078703 | Radiofrequency Ablation |
| D000078702 | Radiofrequency Therapy |
| D013812 | Therapeutics |
| D055011 | Ablation Techniques |
Not provided
Not provided
| OTHER |
| West China Hospital | OTHER |
| Dalian Medical University | OTHER |
| Shanghai Chest Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists | Drug |
|
| 36 month |
| Number of participants with cardiovascular death events | 3 month |
| Number of participants with cardiovascular death events | 12 month |
| Number of participants with cardiovascular death events | 24 month |
| Number of participants with cardiovascular death events | 36 month |
| 24 month |
| recurrence of atrial arrhythmias (AF, AFL, AT) | 36 month |
| resource utilization and costs | 12 month |
| resource utilization and costs | 24 month |
| resource utilization and costs | 36 month |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D013514 |
| Surgical Procedures, Operative |
| D049990 | Membrane Transport Modulators |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
| D000077264 | Calcium-Regulating Hormones and Agents |
| D045505 | Physiological Effects of Drugs |
| D002317 | Cardiovascular Agents |
| D045506 | Therapeutic Uses |